Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 1

Conditions: Neoplasms, Breast

Treatments: Drug: docetaxel; Drug: lapatinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00148902

EGF10021

Details and patient eligibility

About

This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).

Enrollment: 52 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Advanced solid tumors.
• Able to swallow oral medication.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

52 participants in 1 patient group

All treated subjects

Experimental group

Description:

All subjects received Lapatinib in Combination with Docetaxel (Taxotere)

Treatment:

Drug: lapatinib

Drug: docetaxel